At the end of August, Novartis halted several clinical trials of experimental cell therapies for autoimmune diseases in the fields of immunology and neuroscience, following the deaths of three patients.
Novartis halts clinical trials following patient deaths
Keystone-SDA
At the end of August, Novartis halted several clinical trials of experimental cell therapies for autoimmune diseases in the fields of immunology and neuroscience, following the deaths of three patients.
This content was published on
September 1, 2026 - 17:42
Pharmakonzern Novartis stoppt nach Todesfällen mehrere Studien
Novartis pauses trials of experimental cell therapy after three deaths - Health - The Jakarta Post
Novartis, Bristol Myers halt autoimmune CAR-T trials after deaths
Novartis oprește mai multe studii clinice după decese în rândul pacienților - HotNews.ro
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis pausa ensaios de terapia voltada a distúrbios autoimunes e neurológicos após três mortes
Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?
Novartis suspende testes clínicos de medicamento para doenças autoimunes após morte de três pacientes
In der Schweiz sind drei Studienteilnehmer bei einer experimentellen Zelltherapie gestorben – offenbar an einer bekannten…
The halt was implemented on August 24 after Novartis was notified of three cases of a severe, life-threatening immune reaction.…
Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a…
Novartis a suspendat temporar, la sfârșitul lunii august, opt studii clinice pentru o terapie experimentală destinată tratării…
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
